Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation. 5-7 Many commonly used DED treatment options have limitations, including slow onset, patient dissatisfaction and poor adherence. 8-14 Among surveyed dry eye patients, only 13% felt their dry eye was well managed. 14*
'Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care company,' said David Endicott, CEO of Alcon. 'We look forward to making this new treatment available to millions of patients affected by Dry Eye Disease. We believe TRYPTYR is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy.'
This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients (randomized 1:1 to TRYPTYR or vehicle) with a history of DED. 1-2 In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p<0.0001). 1-2 Consistent results were observed at all timepoints through Day 90. TRYPTYR demonstrated statistically significant natural tear production as early as Day 1. 1-2
'Many of my patients continue to face frustrating challenges with dry eye management, and there is a clear need for additional treatment options,' said Marjan Farid, MD, Professor of Ophthalmology at the University of California, Irvine. 'TRYPTYR is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of Dry Eye Disease.'
Studies in animals suggest that acoltremon, the active substance in TRYPTYR, is an agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors. TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action for TRYPTYR in DED is unknown.
TRYPTYR is available in easy-to-use, single dose vials: one drop per eye, two times a day. 3 Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing TRYPTYR to other markets in the future.
INDICATIONS AND USAGE
TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.
Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).
Please click here for the TRYPTYR Full Prescribing Information.
Forward-looking Statements
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'commitment,' 'look forward,' 'maintain,' 'plan,' 'goal,' 'seek,' 'target,' 'assume,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.
About Dry Eye
Dry Eye Disease (DED) is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the U.S. and an estimated 719 million more adults globally. 4 While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender. 15 Many existing prescription options for DED are generally regarded by many Eye Care Professionals and patients as inadequate due to low treatment efficacy, slow onset of action and/or poor tolerability. 16
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
References
*Based on an online survey conducted by Chronic Dry Eye from February to April 2021 among 415 responders who reported being diagnosed with chronic dry eye. 44% reported a severe level of chronic dry eye (i.e., levels 3 and 4).
Data on File for COMET-2 Phase 3 Study. Alcon 2025.
Data on File for COMET-3 Phase 3 Study. Alcon 2025.
TRYPTYR ® U.S. FDA Prescribing Information. 2025.
2023 Dry Eye Products Markets Report, Market Scope, 2023.
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008.
Nattinen J, Aapola U, Nukareddy P, Uusitalo H. Looking deeper into ocular surface health: an introduction to clinical tear proteomics analysis. Acta Ophthalmol. 2022;100:486-498. doi: 10.1111/aos.15059.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510. doi: 10.1016/j.jtos.2017.05.011.
Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76-79. doi: 10.1016/j.ophtha.2006.05.077.
Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083-1094. doi: 10.2147/OPTH.S110557.
Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra ®) in the U.S. and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041-1054. doi: 10.2147/OPTH.S296510.
Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8(3):407-420. doi: 10.1007/s40123-019-0188.
Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, Harrison DJ. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at: American Society for Cataract and Refractive Surgery Conference; April 5-6, 2024; Boston, MA.
Morse H, Henneberger S, Reed J, et al. 2021 in American survey findings: living with chronic dry eye. ChronicDryEye. August 10, 2021. Accessed September 23, 2024. https://chronicdryeye.net/infographic/in-america-findings.
The Relationship Between Dry Eye Disease and Digital Screen Use - PMC (nih.gov).
Improved Dry Eye Drugs for 2022 and Beyond; https://www.aao.org/eye-health/tips-prevention/new-dry-eye-treatments-ocular-surface-disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
21 minutes ago
- Business Wire
ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare
MCKINNEY, Texas--(BUSINESS WIRE)--Human-Like, Real-Time AI Scheduler launched by ScienceSoft ScienceSoft's AI assistant processes 70% more scheduling requests per hour than a human and reduces booking time by 40%. Share ScienceSoft has introduced a HIPAA-compliant AI scheduling assistant that enables natural, human-like conversations with patients. Built on the first-ever integration of Amazon's Nova Sonic speech-to-speech model and the LiveKit Media Server, the assistant supports real-time voice interaction and seamless data exchange with hospital systems. What sets the assistant apart is how it communicates. Most voice agents process speech in separate steps, which slows down the conversation and makes it sound robotic. The model behind our agent is the first to support bidirectional streaming through a single API, enabling listening and responding in real time without delays or awkward pauses. So, the patients get a whole new level of experience. They speak normally and get a timely, helpful response, without the friction they've come to expect from automated systems. The system handles both incoming and outgoing calls, verifies patient identity, checks provider availability, and updates hospital systems during the call. Integration with EHR, CRM, and practice management platforms ensures appointments are confirmed or changed on the spot, without follow-up. The scheduler runs in a secure, HIPAA-compliant cloud environment and is monitored with tools like Amazon Bedrock Guardrails and AWS Macie. Our estimations show the agent can potentially reduce appointment booking time by 40%, cut call abandonment rates by 30%, and lower operational costs by at least 50%. As it can handle multiple calls simultaneously, it is expected to process 70% more calls per hour than a patient service representative. Looking for Insider IT Info? ScienceSoft experts are ready to share practical insights into healthcare technology and patient-facing solutions. Learn how technology is reshaping the way providers interact with patients.
Yahoo
37 minutes ago
- Yahoo
These Foods Will Be Labeled 'Not Recommended for Human Consumption' in Texas
A new law in Texas will require many popular products to have a label warning consumers that it contains ingredients 'not recommended for human consumption.' It targets M&Ms, Doritos, Mountain Dew, and probably at least one of your grocery store guilty pleasures. The law, which was officially signed by Gov. Greg Abbott, requires any food containing one of more than 40 additives to include the label on its packaging by 2027. Here's a closer look at the additives in question, what nutritionists have to say about the MAHA-adjacent legislation, and more. The law aims to align the Lone Star State with the more cautious approach to processed food seen in Europe. There, food additives — like artificial dyes and preservatives — are strictly regulated. The label, which would be found up and down grocery-store aisles, would read: 'WARNING: This product contains an ingredient that is not recommended for human consumption by the appropriate authority in Australia, Canada, the European Union, or the United Kingdom.' The hope is this will nudge manufacturers to strip their items of the additives. These ingredients, which slip through the cracks of a regulatory loophole, have become a priority of the 'Make America Healthy Again' movement. Some major companies — from General Mills to Nestle — have already committed to removing dyes from their products, but the food industry is still pushing back against the law. 'The ingredients used in the U.S. food supply are safe and have been rigorously studied following an objective science- and risk-based evaluation process,' the Consumer Brands Association trade group wrote in a letter to Abbott. 'The labeling requirements of SB 25 mandate inaccurate warning language, create legal risks for brands and drive consumer confusion and higher costs.' The regulation would only apply to food labels 'developed or copyrighted' on or after Jan. 1, 2027 — meaning that companies would only have to include the warning on food labels they've redesigned or updated, like when new ingredients are added, the Washington Post reports. In general, the move to pay closer attention to these ingredients has been applauded by experts, says Kathleen Melanson, a professor of nutrition at the University of Rhode Island. 'Nutrition professionals and other health organizations have been advocating for more scrutiny of food additives for a long time,' she tells us. However, Dr. Melanson and others in her field say they're not quite sure how state legislators came up with their list of 44 ingredients. And there appear to be some discrepancies. The Associated Press reports that three of the additives — partially hydrogenated oils, Red Dye No. 4, and Red Dye No. 3 — have already been restricted in the U.S., and that some of the other ingredients are allowed in Australia, Canada, the E.U., or U.K. A whole range of artificial dyes are included, from Red No. 3 to Yellow No. 5, which have been controversial for some time. That's because they've been linked to hyperactivity and neurobehavioral issues in children and cancer risk. However, the research supporting this is limited, and some of it has only been proven in animals, Dr. Melanson says. There are several preservatives that have been blacklisted, like butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA), which prevent fats in food from going bad. Both ingredients have also been linked to cancer — although, again, in studies on animals, not humans — and BHA is being reviewed in the E.U. for its potential to disrupt hormones. Emulsifiers (or chemicals that help water and oil blend), thickeners, and stabilizers also made the list. Some of these compounds, like propylene glycol, have been linked to allergic reactions and could worsen the symptoms of kidney and liver disease. You can see the full list of 44 additives that would get a warning label here. Dr. Melanson sees the focus on additives as a net positive, but she believes that the more important takeaway for consumers is to minimize the amount of ultra-processed foods in their diets. 'Whether or not a food has a certain dye in it, the main focus should be on getting enough fiber, protein, and other nutrients you need from whole foods,' she says. The post These Foods Will Be Labeled 'Not Recommended for Human Consumption' in Texas appeared first on Katie Couric Media.
Business Wire
an hour ago
- Business Wire
Japan Delegation Concludes Visit to North Carolina to Explore Life Sciences Partnerships
ATLANTA--(BUSINESS WIRE)--A high-level Japanese delegation specializing in life sciences concluded a three-day visit to North Carolina (June 24–26), further strengthening ties between Japanese and U.S. leaders in the sector. Organized by the Japan External Trade Organization (JETRO) and co-organized by the Economic Development Partnership of North Carolina (EDPNC), the Research Triangle Regional Partnership, Greater Winston-Salem, Inc., and the Charlotte Regional Business Alliance, the visit included tours of key facilities within North Carolina's thriving life sciences ecosystem. The delegation commenced its visit with a meeting with Governor Josh Stein, followed by a tour of the North Carolina Plant Sciences Building at North Carolina State University and the Biomanufacturing Training and Education Center (BTEC), where they explored academic–industry collaboration in workforce development. The group also visited Spark LS, a 109-acre advanced life science campus, FUJIFILM Diosynth Biotechnologies, and Astellas Gene Therapies. On the second day, the delegation visited the Innovation Quarter in Winston-Salem and toured the Wake Forest Institute for Regenerative Medicine (WFIRM) to gain insights into cutting-edge initiatives in regenerative medicine. Additional site visits included Winston Starts, Ricoh, Mercodia, and Charter Medical. The day concluded with a warm welcome from Mayor Allen Joines. On the final day, the delegation visited the North Carolina Research Campus in Kannapolis and toured the North Carolina Food Innovation Lab. They also visited Coddle Creek Capital and the University of North Carolina Nutrition Research Institute. The visit concluded at The Pearl, Charlotte's emerging hub for healthcare innovation and scientific advancement. JETRO looks forward to deepening its collaboration with the State of North Carolina, building on the growing momentum between Japan and the region in advanced technology sectors.
